{"title":"Selective versus universal vaccination for varicella zoster virus infection: what holds the key to successful disease control?","authors":"Mark Schleiss","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 2","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Congenital cytomegalovirus infection and hearing loss.","authors":"Robert F Pass","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sensorineural hearing loss is the most frequent sequela of congenital cytomegalovirus (CMV) infection, and epidemiological evidence also suggests that congenital CMV infection is responsible for a substantial proportion of sensorineural hearing loss in children. Hearing loss due to congenital CMV infection can be present at birth or can appear later, usually during the first year of life; it usually worsens as the infant or child ages. Follow-up of children with congenital CMV infection should include repeated audiological testing. Based on the benefits of early detection of hearing loss, one could propose screening all infants for congenital CMV infection so that those with hearing impairment can be identified as early as possible by appropriate audiological follow-up. Antiviral treatment that could improve hearing outcome, with a safety profile suitable for use in minimally ill infants, would clearly increase the benefit of universal screening for congenital CMV infection.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 2","pages":"50-5"},"PeriodicalIF":0.0,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leonardo Emberti Gialloreti, Maurizio Divizia, Francesca Pica, Antonio Volpi
{"title":"Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy.","authors":"Leonardo Emberti Gialloreti, Maurizio Divizia, Francesca Pica, Antonio Volpi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Varicella is the most widespread childhood disease in Italy. However, as in many parts of the world, the country does not yet have a unified approach to the management of the disease. A cost-effectiveness analysis of varicella vaccination strategies, using the Latium region in Italy as a case study, was undertaken. Mass vaccination is only recommended if the immunization programme can achieve coverage of over 85% in a short time. However, experience in Italy with non-compulsory vaccinations has shown this is difficult to achieve. Consequently, eradication of the disease is not seen as an attainable short-term goal. For mass varicella vaccination to be successful, it must be run at a national as well as regional level in combination with education programmes, and a reliable surveillance system. The interaction between varicella and herpes zoster must also be taken into account when considering vaccination strategies, as zoster vaccination strategies may have an impact on varicella coverage.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 2","pages":"33-7"},"PeriodicalIF":0.0,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michelle M Perfect, Nigel Bourne, Charles Ebel, Susan L Rosenthal
{"title":"Use of complementary and alternative medicine for the treatment of genital herpes.","authors":"Michelle M Perfect, Nigel Bourne, Charles Ebel, Susan L Rosenthal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Conventional antiviral drugs have proven effectiveness for genital herpes; however, patients continue to use a variety of complementary and alternative medicine (CAM) treatments. Given that patients may be using these products, it is important that healthcare providers become familiar with the data regarding safety and efficacy. We have reviewed available scientific data on six commonly used treatments (echinacea, eleuthero, L-lysine, zinc, bee products and aloe). In addition, information about a number of other products is presented in tabular form. Currently, there are insufficient clinical data to be confident of the efficacy and safety of any of these products for the treatment of genital herpes. It is hoped that future clinical trials will be conducted with sufficient rigour to provide guidance to the patients using these products.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 2","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Setting standards for the development and use of complementary and alternative therapies in herpes.","authors":"Simon Barton","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 2","pages":"31"},"PeriodicalIF":0.0,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genital herpes in young adults: changing sexual behaviours, epidemiology and management.","authors":"Craig Roberts","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Genital herpes is a common sexually transmitted infection throughout the world. The majority of new infections occur in adolescents and young adults, although prevalence rates generally increase with age and cumulative sexual experience. In young adults, herpes simplex virus 1 (HSV-1) infection is becoming a more common cause of genital herpes. Reasons for this trend include changing sexual practices, notably oral-genital exposure and the use of condoms for intercourse. Important implications of having genital herpes include the risk of transmission to sexual partners and the increased risk of acquiring and transmitting HIV. Genital herpes infections are often unrecognized, and transmission to uninfected partners is likely to occur during asymptomatic shedding. A diagnosis of herpes may also affect psychosexual development, particularly in adolescents. Such factors contribute to the growing global HSV prevalence and suggest a need to implement better screening programmes in young adults. Recognizing and treating HSV early offers benefits to patients and their sexual partners by reducing the frequency and severity of outbreaks, limiting the likelihood of disease transmission, and preventing new infections.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 1","pages":"10-4"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25197418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mary B Short, Richard Rupp, Lawrence R Stanberry, Susan L Rosenthal
{"title":"Parental acceptance of adolescent vaccines within school-based health centres.","authors":"Mary B Short, Richard Rupp, Lawrence R Stanberry, Susan L Rosenthal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Parental acceptability of genital herpes (HV) and meningococcal (MV) vaccines within school-based health centres (SBHCs) was examined. A convenience sample of 85 parents completed a telephone survey. Eighty-five per cent of respondents supported offering the HV within SBHCs; 87% the MV. Sixty-two per cent of respondents would allow HV to be administered to their adolescent in the SBHC, 75% the MV. When location of vaccination was unspecified, 42% of parents would allow vaccination of their adolescent for HV, and 71% would permit MV vaccination. Parents supported offering HV via SBHCs; many would permit their adolescent to receive it. Predictors included SBHC perceptions and a belief that all adolescents should be vaccinated for genital herpes. Perceptions of stigma/shame associated with sexually transmitted infections were not related to herpes vaccine acceptability. Efforts to enhance vaccine uptake for adolescents should focus on promoting positive perceptions of the location of vaccination and universal recommendations.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 1","pages":"23-7"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25197343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic.","authors":"Simon Barton, Connie Celum, Timothy W Shacker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The management of genital herpes in patients co-infected with human immunodeficiency virus (HIV) varies considerably from those without HIV infection. The International Herpes Management Forum (IHMF) has published guidelines for the diagnosis and management of herpes simplex virus (HSV) infection in the HIV-infected host. In 2004, these recommendations were supplemented after consideration of the most recent research conducted in this field, which adds to the growing body of evidence linking the epidemics of HSV-2 and HIV-1 infection. This article presents the supporting evidence for these recommendations and statements. Recent studies suggest that HSV-2 infection may elevate viral load during HIV-1 infection and hence lead to accelerated disease progression. It therefore seems logical to offer suppressive antiviral therapy routinely to HIV-positive patients. This approach is supported by studies demonstrating the safety and efficacy of HSV antiviral therapy in individuals co-infected with HSV and HIV. The question remains whether HSV antiviral therapeutics reduce the risk of HIV acquisition and transmission. Clinical trials are being conducted to address this question. HSV type-specific serological testing is warranted in those who are infected with, or who are at high risk of acquiring, HIV infection. However, in developing countries and resource-poor settings, their utility is less clear for a number of reasons. These aspects are also discussed.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 1","pages":"15-22"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25197421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human herpesviruses, HIV, vaccinations and multiple sclerosis.","authors":"Jean-Elie Malkin","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25197413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease.","authors":"Julie Fotheringham, Steven Jacobson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a debilitating neurological disease of unknown cause that affects people between 20 and 40 years of age. While several viruses have been associated with MS, none has proven causative. Human herpesvirus 6 (HHV-6) is one agent that may play a role in MS. Some studies have demonstrated an association between HHV-6 and MS based on immunological and molecular data, suggesting that a subset of MS patients may have reactivation of this widespread herpesvirus. New studies investigating the biology of HHV-6 have given insights towards understanding how HHV-6 may play a role in MS pathology. By inducing molecular mimicry or excessive complement activation, HHV-6 reactivation may have the potential to trigger autoimmunity and tissue damage associated with MS lesion development.</p>","PeriodicalId":83725,"journal":{"name":"Herpes : the journal of the IHMF","volume":"12 1","pages":"4-9"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25197416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}